[HTML][HTML] IL-1 receptor antagonist anakinra in the treatment of COVID-19 acute respiratory distress syndrome: a retrospective, observational study
M Franzetti, A Forastieri, N Borsa… - The Journal of …, 2021 - journals.aai.org
The IL-1 receptor antagonist, anakinra, may represent a therapeutic option for acute
respiratory distress syndrome (ARDS) associated with coronavirus disease 2019 (COVID …
respiratory distress syndrome (ARDS) associated with coronavirus disease 2019 (COVID …
Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia
As of April 1, 2020, 885,689 cases of infections by the novel coronavirus SARS-CoV-2
(COVID-19) have been recorded worldwide; 44,217 of them have died (https://www …
(COVID-19) have been recorded worldwide; 44,217 of them have died (https://www …
Sarilumab use in severe SARS-CoV-2 pneumonia
Background Interleukin-6 signal blockade showed preliminary beneficial effects in treating
inflammatory response against SARS-CoV-2 leading to severe respiratory distress. Herein …
inflammatory response against SARS-CoV-2 leading to severe respiratory distress. Herein …
Soluble urokinase receptor (SuPAR) in COVID-19–related AKI
Background AKI commonly occurs in patients with coronavirus disease 2019 (COVID-19). Its
pathogenesis is poorly understood. The urokinase receptor system is a key regulator of the …
pathogenesis is poorly understood. The urokinase receptor system is a key regulator of the …
Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial
S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu… - Jama, 2023 - jamanetwork.com
Importance The longer-term effects of therapies for the treatment of critically ill patients with
COVID-19 are unknown. Objective To determine the effect of multiple interventions for …
COVID-19 are unknown. Objective To determine the effect of multiple interventions for …
Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure
EJ Giamarellos-Bourboulis, G Poulakou… - Cell Reports …, 2022 - cell.com
Most patients infected with SARS-CoV-2 (COVID-19) experience mild, non-specific
symptoms, but many develop severe symptoms associated with an excessive inflammatory …
symptoms, but many develop severe symptoms associated with an excessive inflammatory …
IL-6 receptor antagonist therapy for patients hospitalized for COVID-19: who, when, and how?
MA Matthay, AF Luetkemeyer - JAMA, 2021 - jamanetwork.com
(IL-6), based on the hypothesis that SARS-CoV-2 creates injury to the lung and other organs
in part through activation of cytokine and downstream proinflammatory networks. While …
in part through activation of cytokine and downstream proinflammatory networks. While …
Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial
Background Patients with COVID-19 pneumonia can have increased inflammation and
elevated cytokines, including interleukin (IL)-6, which might be deleterious. Thus, sarilumab …
elevated cytokines, including interleukin (IL)-6, which might be deleterious. Thus, sarilumab …
[HTML][HTML] Anakinra in COVID-19: important considerations for clinical trials
The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has caused more than 320 000 deaths as of May 19, 2020. COVID-19 deaths …
(SARS-CoV-2) has caused more than 320 000 deaths as of May 19, 2020. COVID-19 deaths …
Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a systematic review and meta-analysis
F Barkas, S Filippas-Ntekouan, M Kosmidou… - …, 2021 - academic.oup.com
Objectives Acute respiratory distress syndrome and cytokine release syndrome are the
major complications of coronavirus disease 2019 (COVID-19) associated with increased …
major complications of coronavirus disease 2019 (COVID-19) associated with increased …